Breaking Corporate Events, Analysed in Real Time

Alembic Pharmaceuticals Q1 Revenue Jumps 26% as US Generics Surge 49% YoY

Alembic Pharmaceuticals delivered a strong Q1 FY27 performance with consolidated revenue reaching INR 2,150 Cr. The growth was spearheaded by a 49% surge in the US Generics business and a 33% increase in the API segment, leading management to raise the overall annual growth guidance.

Lupin Limited Reports 32% Q4 Revenue Growth as FY26 EBITDA Surges 68%

Lupin Limited delivered a record-breaking performance in FY26, characterized by significant surges in US generic sales and a robust prescription business in India. While the company exceeded margin guidance for the year, management has signaled a more conservative stance for FY27 to account for upcoming competitive pressures in key product categories.